ClinicalTrials.gg
Not yet recruitingNCT07715994Updated Jul 21, 2026

A Computer-Assisted Tool for Objective Assessment of Extrapyramidal Symptoms

An observational study in Extrapyramidal Symptoms, Drug-induced Parkinsonism and Akathisia, Drug-Induced, sponsored by Shanghai Mental Health Center. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Shanghai Mental Health Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
180
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Tardive Dyskinesia with a site in China — 3 open to participants now, 3 under way, none of them phase 3. Tardive Dyskinesia · China.

Started
2026
the only one that year
Observational
Only one
of the 10
Registered
10th of 10
by date
Lead sponsor
2 of 10
Shanghai Mental Health Center

Among the 10 studies in Tardive Dyskinesia with a site in China, this one is the only one that started in 2026, is the only observational one, and was the 10th registered.

Tardive Dyskinesia

62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.

Browse Tardive Dyskinesia studies →

Open to participants now

3 of the 10 studies in Tardive Dyskinesia with a site in China are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Tardive Dyskinesia with a site in China, or all of them as a file.
02

Study summary

This prospective, single-center observational study aims to develop and validate a computer-assisted tool for the objective quantitative assessment of extrapyramidal symptoms (EPS).

The study will enroll 180 participants, including 90 healthy controls and 90 participants with clinically confirmed antipsychotic-induced EPS. The healthy control group will provide reference data on normal movement, while the EPS disease group will provide data on abnormal movements associated with drug-induced parkinsonism, akathisia, or tardive dyskinesia.

Each participant will complete one study visit lasting approximately 60 minutes. During the visit, a trained psychiatrist will assess EPS using the Simpson-Angus Scale (SAS), Barnes Akathisia Rating Scale (BARS), and Abnormal Involuntary Movement Scale (AIMS). Participants will also complete standardized movement tasks while a non-contact computer vision system records and analyzes movement features. The device-based assessment will be repeated after a short rest to evaluate the stability of the measurements.

Data collected earlier in the study will be used to develop and optimize the assessment tool. After the algorithm is finalized and locked, data from subsequently enrolled participants will be used for independent validation. The study will evaluate how closely the tool's results agree with clinician assessments, as well as its ability to identify EPS, produce stable repeated measurements, and operate feasibly and safely in a clinical setting.

This is an observational study. The study does not assign treatment, change participants' medications, or use the investigational tool to make treatment decisions.

Read the detailed description

This is a prospective, single-center, two-cohort observational study designed to develop and validate an objective quantitative assessment and computer-assisted diagnostic tool for extrapyramidal symptoms (EPS). The study focuses on EPS associated with antipsychotic treatment, including drug-induced parkinsonism, akathisia, and tardive dyskinesia.The observational study model is classified as Other because this is a two-cohort diagnostic accuracy and tool development and validation study with a single study visit, rather than a conventional longitudinal cohort study.

A total of 180 evaluable participants are planned for enrollment. The study includes two cohorts: 90 healthy controls and 90 participants with clinically confirmed antipsychotic-induced EPS. The healthy control cohort will provide reference data for normal physiological movement and will help establish a baseline for distinguishing normal movement variability from abnormal movement features. The EPS disease cohort will provide positive reference data representing clinically confirmed abnormal movement patterns and different levels of symptom severity. The two cohorts are used as reference populations for tool development and validation and are not treatment comparison groups.

Each participant will complete a single study visit lasting approximately 60 minutes. After written informed consent, demographic and relevant clinical information will be collected. For participants in the EPS disease cohort, information on psychiatric history, antipsychotic treatment, time of the most recent medication dose, and use of medications for EPS will also be recorded.

A trained senior psychiatrist will then conduct standardized clinical EPS assessments using the Simpson-Angus Scale (SAS), Barnes Akathisia Rating Scale (BARS), and Abnormal Involuntary Movement Scale (AIMS). The clinical assessment includes observation of posture and spontaneous movement, examination of orofacial movements, standardized upper-limb and hand movements, standing and walking tasks, and assessment of subjective symptoms when applicable. Clinician ratings will be recorded separately from the device assessment, and device operators will not have access to the clinician ratings during data collection.

Participants will subsequently complete a standardized device-based assessment using a non-contact image-based computer vision system. The assessment tasks are designed as a digital representation of movement features examined during routine clinical EPS assessment. Tasks include standardized periods of sitting, upper-limb positioning and movement, orofacial movements such as mouth opening and tongue protrusion, hand and finger movements, standing, walking, and turning. The system extracts facial, hand, and body keypoint information and derives quantitative movement and kinematic features.

After the first device-based assessment, participants will have a short rest of approximately 5 minutes. When physically able and willing to continue, they will complete a second assessment using the same device, instructions, and task sequence. The repeated assessment will be used to evaluate the stability and repeatability of the device-based measurements.

The study uses a two-stage development and validation design. Approximately the first 70% of evaluable participants, including participants from both cohorts, will contribute data to the tool development stage. Device-derived movement features will be aligned with clinician-rated SAS, BARS, and AIMS results to support model training, parameter optimization, and development of objective severity grading. After the predefined development process is completed, the algorithm will be locked and no further model modification will be made for the validation analysis.

Approximately the final 30% of evaluable participants enrolled after algorithm lock will form an independent validation set. The locked system will be evaluated on these previously unseen data. The validation stage will assess agreement between device-based and clinician-rated EPS severity grading, the ability of the tool to distinguish participants with clinically confirmed EPS from healthy controls, the stability of repeated measurements, and the feasibility and safety of the standardized assessment procedure.

This is a non-interventional observational study. Participants are not assigned to treatments or medications by the study protocol. The study does not require discontinuation, dose reduction, dose escalation, or substitution of antipsychotic or anti-EPS medications. Outputs from the investigational system will be used for research purposes and will not be used to make immediate clinical treatment decisions.

03

Conditions studied

  • Extrapyramidal Symptoms
  • Drug-induced Parkinsonism
  • Akathisia, Drug-Induced
  • Tardive Dyskinesia (TD)

Browse trials for

Keywords

  • Antipsychotic-Induced Extrapyramidal Symptoms
  • Objective Quantitative Assessment
  • Computer-Assisted Diagnosis
  • Computer Vision
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of a Control Group and an EPS Disease Group recruited at Shanghai Mental Health Center. Potential participants in the EPS Disease Group will be identified and screened by research physicians in relevant outpatient clinics, inpatient wards, and other institutionally approved recruitment settings. Participants in the Control Group may be recruited through institutionally approved notices or by study researchers. Eligibility will be confirmed according to the predefined inclusion and exclusion criteria. A total of 180 evaluable participants are planned, including 90 participants in the Control Group and 90 participants in the EPS Disease Group.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A. Control Group

  1. Aged 18 to 80 years, with no restriction on sex.
  2. No current or past history of a psychiatric disorder meeting ICD-10 or criteria.
  3. No current or past history of central nervous system disease, such as primary Parkinson's disease or epilepsy, and no severe physical illness.
  4. No use within the 3 months before screening of medications that may cause extrapyramidal symptoms, such as antipsychotics or certain antiemetic medications.
  5. Sufficient visual, auditory, and cognitive ability to understand and cooperate with the standardized device-side assessment task sequence.
  6. Full understanding of the purpose and exploratory research nature of the study, voluntary participation, and provision of written .

B. EPS Disease Group

  1. Aged 18 to 80 years, with no restriction on sex.
  2. Diagnosis of schizophrenia or a related psychotic disorder according to ICD-10 criteria.
  3. Regular treatment with one or more antipsychotic medications for at least 4 weeks.
  4. Clinically confirmed antipsychotic-induced extrapyramidal symptoms meeting at least one of the following criteria:

    1. Drug-induced parkinsonism: a total score of 2 or higher on Items 1, 2, 3, 4, 5, and 9 of the Simpson-Angus Scale (SAS).
    2. Akathisia: a score of 2 or higher on the Global Clinical Assessment item of the Barnes Akathisia Rating Scale (BARS).
    3. Tardive dyskinesia: a score of 3 or higher on any one of Items 1 through 7 of the Abnormal Involuntary Movement Scale (AIMS), or a score of 2 or higher on any two of these items.
  5. Sufficient visual, auditory, and cognitive ability to understand and cooperate with the standardized device-side assessment task sequence.
  6. Full understanding of the purpose and exploratory research nature of the study, voluntary participation, and provision of written informed consent by the participant or, where applicable, the participant's legal guardian.

Exclusion criteria

Exclusion Criteria

The following exclusion criteria apply to both groups:

  1. Primary neurological or organic movement disorders that may affect the assessment results, such as primary Parkinson's disease, Huntington's disease, Wilson's disease, or sequelae of stroke.
  2. Severe musculoskeletal disease, recent fracture, limb disability, or other physical conditions that prevent completion of the required assessment tasks.
  3. Acute exacerbation of psychiatric symptoms with severe agitation, impulsivity, stupor, or severe cognitive impairment that prevents safe and adequate cooperation with the assessment.
  4. Severe deformity of the face or tested limbs, large dark-colored tattoos, or severe non-removable occlusion that may substantially interfere with computer-vision-based assessment.
  5. Poorly fitting removable dentures or frequent compensatory oral movements that may interfere with objective assessment of orofacial movements.
  6. Any condition that, in the investigator's judgment, may affect participant safety, substantially compromise data quality, or make the individual unsuitable for participation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
180 participants (estimated)
Patient registry
No

Groups and cohorts

  • Control Group

    Participants without current or past psychiatric disorders and without extrapyramidal symptoms associated with antipsychotic treatment. Participants will undergo standardized clinical scale assessments and two repeated device-based movement assessments during a single study visit. Data from this group will provide reference information on normal movement characteristics for development and validation of the objective quantitative assessment and computer-assisted diagnostic tool.

    Diagnostic Test: Computer-Assisted Objective Assessment of Extrapyramidal Symptoms

  • EPS Disease Group

    Participants with schizophrenia or related psychotic disorders who have received regular antipsychotic treatment and have clinically confirmed antipsychotic-induced extrapyramidal symptoms. Eligible symptoms include drug-induced parkinsonism, akathisia, and/or tardive dyskinesia according to predefined clinical criteria. Participants will undergo standardized clinical scale assessments and two repeated device-based movement assessments during a single study visit. Data from this group will be used for development and validation of the objective quantitative assessment and computer-assisted diagnostic tool.

    Diagnostic Test: Computer-Assisted Objective Assessment of Extrapyramidal Symptoms

Interventions

  • Diagnostic testComputer-Assisted Objective Assessment of Extrapyramidal Symptoms

    Participants will complete a standardized, non-contact, image-based computer-assisted assessment of extrapyramidal symptoms. The assessment consists of predefined sitting, orofacial, hand and finger, upper-limb, standing, walking, and turning tasks. The system processes image data to extract facial, hand, and body keypoints and derive quantitative movement and kinematic features. Each participant will complete the same assessment twice during a single study visit, separated by approximately 5 minutes, to evaluate test-retest reliability. The assessment is conducted for research purposes only. It does not assign or modify treatment, and its outputs will not be used to make immediate clinical treatment decisions.

06

What researchers measure

Primary outcomes

  1. Maximum Weighted Kappa Coefficient Across Three EPS Subtype-Specific Device-Clinical Severity Classification Comparisons

    The primary outcome is a single aggregated agreement metric defined as the maximum weighted kappa coefficient among three prespecified subtype-specific comparisons. Weighted kappa coefficients with 95% confidence intervals will be calculated separately for: (1) device-side drug-induced parkinsonism severity classification versus Simpson-Angus Scale (SAS)-based classification; (2) device-side akathisia severity classification versus Barnes Akathisia Rating Scale (BARS)-based classification; and (3) device-side tardive dyskinesia severity classification versus Abnormal Involuntary Movement Scale (AIMS)-based classification. The maximum of the three weighted kappa coefficients will be reported as the primary outcome in the independent test set after algorithm locking. The prespecified primary success criterion will be met if at least one of the three subtype-specific weighted kappa coefficients reaches or exceeds the predefined agreement threshold.

    Time frame: Single study visit, Day 1

Secondary outcomes

  1. Test-Retest Reliability of Device-Side Repeated Acquisition Results

    Participants will complete two identical standardized device-side motion acquisitions during the same study visit. The intraclass correlation coefficient (ICC) will be calculated for continuous motion features generated by the two acquisitions. Weighted kappa will be calculated for predicted classification results to evaluate short-term stability.

    Time frame: Two assessments during the single study visit, separated by approximately 5 minutes, Day 1

  2. Sensitivity of the Device-Side System for Identifying EPS

    Using the prespecified SAS-, BARS-, and AIMS-based clinical criteria as the reference standard, sensitivity will be calculated as true positives divided by true positives plus false negatives, multiplied by 100, with a 95% confidence interval. Analysis will use the independent test set after algorithm locking.

    Time frame: Single study visit, Day 1

  3. Specificity of the Device-Side System for Identifying EPS

    Using the prespecified SAS-, BARS-, and AIMS-based clinical criteria as the reference standard, specificity will be calculated as true negatives divided by true negatives plus false positives, multiplied by 100, with a 95% confidence interval. Analysis will use the independent test set after algorithm locking.

    Time frame: Single study visit, Day 1

  4. Accuracy of the Device-Side System for Identifying EPS

    Using the prespecified clinical reference standard, accuracy will be calculated as true positives plus true negatives divided by the total number of evaluated participants, multiplied by 100, with a 95% confidence interval. Analysis will use the independent test set after algorithm locking.

    Time frame: Single study visit, Day 1

  5. Positive Predictive Value of the Device-Side System for Identifying EPS

    Positive predictive value will be calculated as true positives divided by true positives plus false positives, multiplied by 100, with a 95% confidence interval. Analysis will use the independent test set after algorithm locking.

    Time frame: Single study visit, Day 1

  6. Negative Predictive Value of the Device-Side System for Identifying EPS

    Negative predictive value will be calculated as true negatives divided by true negatives plus false negatives, multiplied by 100, with a 95% confidence interval. Analysis will use the independent test set after algorithm locking.

    Time frame: Single study visit, Day 1

  7. Area Under the Receiver Operating Characteristic Curve for the Device-Side System in Identifying EPS

    A receiver operating characteristic curve will be generated using a continuous output produced by the locked device-side system and the binary clinical reference classification. The area under the curve will be calculated with a 95% confidence interval in the independent test set after algorithm locking. Higher values indicate better discrimination.

    Time frame: Single study visit, Day 1

  8. Number of Participants With One or More Adverse Events During Study Procedures

    The number of participants experiencing at least one adverse event during the study visit will be recorded. Potential events include falls, gait instability, muscle fatigue or soreness, anxiety, fear, agitation, refusal to undergo testing, and transient fluctuation of psychiatric symptoms. Severity, management, outcome, and relationship to study procedures will be summarized descriptively.

    Time frame: Throughout the single study visit, approximately 60 minutes, Day 1

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared with other researchers because the study involves potentially identifiable facial and body movement data from psychiatric participants. Original images and key frame images will not be publicly shared or transferred outside the study institution. No external individual-level data sharing mechanism is currently planned.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Apr 2027, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2026
First posted
Jul 21, 2026
StartEst.
Jul 2026
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07715994
Responsible party
Sponsor
First posted
Jul 21, 2026
Start date
Jul 2026 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Jul 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion